New-generation Genomic Test for Treatment Decision-making in Early Breast Cancer – Contribution of the Prosigna® (PAM50) Gene Signature Assay
LONDON, November 10, 2015 (PRNewswire) European Oncology & Haematology Review, a peer-reviewed journal, has published a review highlighting the benefits of the Prosigna® (PAM50) Gene Signature Assay, a new-generation genomic test for treatment decision-making in early breast cancer